Rebecca Isaacson, NP
Nurse Practitioner · Provo, UTNPI 1265907497
Payments from drug & device makers
Across 72 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$278
- Dexcom, Inc.$275
- Insulet Corporation$249
- Tandem Diabetes Care, Inc.$192
- BETA Bionics, Inc.$107
- Lilly USA, LLC$87
- plus $379 from 13 others
What the payments were for
- Food & beverage$1,50196%
- Education$121%
- Other$554%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 22 | $278 |
| Dexcom, Inc. | 13 | $275 |
| Insulet Corporation | 2 | $249 |
| Tandem Diabetes Care, Inc. | 4 | $192 |
| BETA Bionics, Inc. | 6 | $107 |
| Lilly USA, LLC | 5 | $87 |
| Bayer | 5 | $71 |
| Sanofi-aventis U.S. LLC | 2 | $46 |
| Novartis | 2 | $39 |
| Boehringer Ingelheim | 2 | $36 |
| Corcept Therapeutics | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Cequr Corporation | 1 | $24 |
| BD | 1 | $23 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Madrigal Pharmaceuticals | 1 | $19 |
| Novo Nordisk | 1 | $17 |
| AstraZeneca | 1 | $17 |
| Ascensia Diabetes Care US Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,568 in reported general payments places this provider in the 80th percentile of 979 nurse practitioner providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 296 | $351,851 |
| JardianceEmpagliflozin | 104 | $107,290 |
| FarxigaDapagliflozin Propanediol | 53 | $56,711 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $46,637 |
| OzempicSemaglutide | 32 | $37,756 |
| Novolog FlexpenInsulin Aspart | 38 | $19,012 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 90 | $13,657 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 18 | $8,556 |
| Humalog Kwikpen U-100Insulin Lispro | 21 | $6,506 |
| Novolog Mix 70-30 FlexpenInsulin Aspart Prot/Insuln Asp | 11 | $5,643 |
| Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm | 18 | $4,920 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 21 | $4,627 |
| NovologInsulin Aspart | 14 | $3,894 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 31 | $3,604 |
| Insulin Aspart FlexpenInsulin Aspart | 13 | $3,133 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $87 | $351,851296 claims |
| Boehringer IngelheimJardiance | $36 | $107,290104 claims |
| AstraZenecaFarxiga | $17 | $56,71153 claims |
| Novo NordiskOzempic, Novolog | $17 | $41,65146 claims |
| Sanofi-aventis U.S. LLCLantus | $46 | $2,77622 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 979 nurse practitioner providers in Utah.
Other nurse practitioner in Provo
- Clarene HansenProvo$11K
- Steven LarsenProvo$11K
- James BiesingerProvo$11K
- Tracy WilliamsProvo$9K
- Valerie JuarezProvo$7K
- Nancy MortensenProvo$5K
- April JensenProvo$5K
- Ann RogersonProvo$4K
- Nancy TrotterProvo$4K
- David GambleAmerican Fork$836K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.